Technology areas: Biotechnology & Pharmaceuticals • Communications
19 pending office actions • 17 art units • 18 examiners • 0 of 19 (0%) have an AI response strategy ready • 36 patents granted in the last 365 days
Ulthera, Inc. has 4 pending office actions in the Medical Devices & Mechanical Engineering technology area. These are handled by 2 distinct examiners in 1 distinct art unit. MOHAMMED, SHAHDEEP is the busiest examiner, responsible for 3 pending office actions. This means MOHAMMED, SHAHDEEP handles 3 of the 4 total pending actions for the company, creating a level of examiner concentration for this portfolio.
The focus on 1 distinct art unit and the concentration of 3 actions under MOHAMMED, SHAHDEEP suggests a specific technological niche for these filings. With only 2 distinct examiners involved in the 4 pending office actions, the company has an opportunity to develop a consistent prosecution strategy. The influence of MOHAMMED, SHAHDEEP is strong, as this single examiner oversees 3 of the 4 currently pending matters in the medical device field.
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 3 (16%) |
| §103 only | 4 (21%) |
| §102 only | 1 (5%) |
| §112 only | 2 (11%) |
| Multi-statute (no §101) | 8 (42%) |
| No statute on record | 1 (5%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| NGUYEN, NAM P | 2 | 54.8% | +48.7% |
| NAH, JONGBONG | 1 | 76.0% | +17.5% |
| CESE, KENNY A | 1 | 75.2% | +11.0% |
| REYES, REGINALD R | 1 | 40.9% | +31.5% |
| KUDO, KEN | 1 | — | — |
| BOYAR, NOAH WILLIAM | 1 | 100.0% | +0.0% |
| DESIRE, GREGORY M | 1 | 90.6% | +6.1% |
| SAOUD, CHRISTINE J | 1 | 57.9% | +37.5% |
| HAQ, SHAFIQUL | 1 | 64.8% | +55.2% |
| OLSON, ANDREA STEFFEL | 1 | 62.4% | -11.9% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18887979 | MULTI-CLASS INTERACTIVE SEGMENTATION GRAPHICAL USER INTERFACE | DESIRE, GREGORY M | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17222536 | HEMATOXYLIN STAINER SYSTEM | HERON, VELVET ELIZABETH | 98d overdue |
| 19038628 | SYSTEM AND METHOD FOR QUANTIFICATION OF DIGITIZED PATHOLOGY SLIDES | CESE, KENNY A | — |
| 19009479 | REPRESENTATIVE DATASETS FOR BIOMEDICAL MACHINE LEARNING MODELS | REYES, REGINALD R | — |
| 19003361 | ARCHITECTURE-AWARE IMAGE TILING FOR PROCESSING PATHOLOGY SLIDES | KUDO, KEN | — |
| 18976550 | ADAPTIVE LEARNING FRAMEWORK FOR DIGITAL PATHOLOGY | BOYAR, NOAH WILLIAM | — |
| 18373328 | PROXIMITY ASSAYS USING CHEMICAL LIGATION AND HAPTEN TRANSFER | HAQ, SHAFIQUL | — |
| 18232909 | QUINONE METHIDE ANALOG SIGNAL AMPLIFICATION | OLSON, ANDREA STEFFEL | — |
| 18028971 | CELL DEPOSITION AND IMAGING APPARATUS | EDWARDS, LYDIA E | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 7 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 16442091 | METHODS AND SYSTEMS FOR QUANTITATIVE IMMUNOHISTOCHEMISTRY | NGUYEN, NAM P | 38d overdue |
| 19076883 | EXPRESSION-LEVEL PREDICTION FOR BIOMARKERS IN DIGITAL PATHOLOGY IMAGES | NAH, JONGBONG | — |
| 19038628 | SYSTEM AND METHOD FOR QUANTIFICATION OF DIGITIZED PATHOLOGY SLIDES | CESE, KENNY A | — |
| 19009479 | REPRESENTATIVE DATASETS FOR BIOMEDICAL MACHINE LEARNING MODELS | REYES, REGINALD R | — |
| 18617474 | MULTIPLEXED IMMUNOHISTOCHEMISTRY USING RECOMBINANT ANTIBODIES WITH EPITOPE TAGS | SAOUD, CHRISTINE J | — |
| 18373328 | PROXIMITY ASSAYS USING CHEMICAL LIGATION AND HAPTEN TRANSFER | HAQ, SHAFIQUL | — |
| 17966904 | PEPTIDE NUCLEIC ACID CONJUGATES | NGUYEN, NAM P | — |
| Art Unit | Apps |
|---|---|
| 1678 | 3 |
| 2674 | 1 |
| 2663 | 1 |
| 3684 | 1 |
| 2671 | 1 |
| 2669 | 1 |
| 2676 | 1 |
| 1600 | 1 |
| 1693 | 1 |
| 2872 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19076883 | EXPRESSION-LEVEL PREDICTION FOR BIOMARKERS IN DIGITAL PATHOLOGY IMAGES | NAH, JONGBONG | 2674 | §103 | Non-Final OA | — | Pending | Mar 11, 2025 |
| 19038628 | SYSTEM AND METHOD FOR QUANTIFICATION OF DIGITIZED PATHOLOGY SLIDES | CESE, KENNY A | 2663 | §101§102§103 | Non-Final OA | — | Pending | Jan 27, 2025 |
| 19009479 | REPRESENTATIVE DATASETS FOR BIOMEDICAL MACHINE LEARNING MODELS | REYES, REGINALD R | 3684 | §101§102Other | Non-Final OA | — | Pending | Jan 03, 2025 |
| 19003361 | ARCHITECTURE-AWARE IMAGE TILING FOR PROCESSING PATHOLOGY SLIDES | KUDO, KEN | 2671 | §102§112 | Non-Final OA | — | Pending | Dec 27, 2024 |
| 18976550 | ADAPTIVE LEARNING FRAMEWORK FOR DIGITAL PATHOLOGY | BOYAR, NOAH WILLIAM | 2669 | §103§112 | Non-Final OA | — | Pending | Dec 11, 2024 |
| 18887979 | MULTI-CLASS INTERACTIVE SEGMENTATION GRAPHICAL USER INTERFACE | DESIRE, GREGORY M | 2676 | §102 | Non-Final OA | — | Pending | Sep 17, 2024 |
| 18617474 | MULTIPLEXED IMMUNOHISTOCHEMISTRY USING RECOMBINANT ANTIBODIES WITH EPITOPE TAGS | SAOUD, CHRISTINE J | 1600 | §112 | Final Rejection | — | Pending | Mar 26, 2024 |
| 18373328 | PROXIMITY ASSAYS USING CHEMICAL LIGATION AND HAPTEN TRANSFER | HAQ, SHAFIQUL | 1678 | §102§103§112 | Non-Final OA | — | Pending | Sep 27, 2023 |
| 18232909 | QUINONE METHIDE ANALOG SIGNAL AMPLIFICATION | OLSON, ANDREA STEFFEL | 1693 | §102§103 | Final Rejection | — | Pending | Aug 11, 2023 |
| 18036796 | IMAGE SCANNING APPARATUS AND METHOD | NGUYEN, THONG Q | 2872 | §103 | Final Rejection | — | Pending | May 12, 2023 |
| 18028971 | CELL DEPOSITION AND IMAGING APPARATUS | EDWARDS, LYDIA E | 1796 | §102§103§112 | Final Rejection | — | Pending | Mar 28, 2023 |
| 18050425 | HISTOCHEMICAL SYSTEMS AND METHODS FOR EVALUATING EGFR AND EGFR LIGAND EXPRESSION IN TUMOR SAMPLES | CRAWLEY, TALIA F | 3627 | §103 | Non-Final OA | — | Pending | Oct 27, 2022 |
| 17966904 | PEPTIDE NUCLEIC ACID CONJUGATES | NGUYEN, NAM P | 1678 | §102§103§112 | Non-Final OA | — | Pending | Oct 17, 2022 |
| 17895936 | METHOD FOR PREDICTION OF THE PROGRESSION RISK OF TUMORS | GODDARD, LAURA B | 1642 | Other | Non-Final OA | 34d | Pending | Aug 25, 2022 |
| 17805141 | FULLY AUTOMATED NUCLEIC ACID EXTRACTION METHODS FOR TISSUE SAMPLES | POHNERT, STEVEN C | 1683 | §103§112 | Non-Final OA | — | Pending | Jun 02, 2022 |
| 17546735 | CANCER RISK STRATIFICATION BASED ON HISTOPATHOLOGICAL TISSUE SLIDE ANALYSIS | VANNI, GEORGE STEVEN | 1686 | §101§103§112DP | Non-Final OA | — | Pending | Dec 09, 2021 |
| 17222536 | HEMATOXYLIN STAINER SYSTEM | HERON, VELVET ELIZABETH | 1798 | §102§103 | Final Rejection | 98d overdue | Pending | Apr 05, 2021 |
| 15734301 | UNIVERSAL OR NORMALIZED ANTIBODY FRAMEWORKS FOR IMPROVED FUNCTIONALITY AND MANUFACTURABILITY | BRISTOL, LYNN ANNE | 1643 | §112 | Non-Final OA | — | Pending | Dec 02, 2020 |
| 16442091 | METHODS AND SYSTEMS FOR QUANTITATIVE IMMUNOHISTOCHEMISTRY | NGUYEN, NAM P | 1678 | §103 | Non-Final OA | 38d overdue | Pending | Jun 14, 2019 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialUlthera Inc. has 19 pending office actions as of October 2026, spread across 17 art units and 18 examiners.
Nam P Nguyen has the most, with 2 of Ulthera Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
